STOCK TITAN

PAVmed Inc - PAVMZ STOCK NEWS

Welcome to our dedicated news page for PAVmed (Ticker: PAVMZ), a resource for investors and traders seeking the latest updates and insights on PAVmed.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect PAVmed's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of PAVmed's position in the market.

Rhea-AI Summary
PAVmed and Lucid Diagnostics to participate in Cantor Fitzgerald Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.69%
Tags
conferences
-
Rhea-AI Summary
PAVmed and Lucid Diagnostics to participate in Cantor Fitzgerald Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.56%
Tags
conferences
-
Rhea-AI Summary
Lucid Diagnostics Inc. has released positive interim data from the multicenter CLUE study, demonstrating the real-world clinical utility of EsoGuard Esophageal DNA testing. The study shows excellent concordance between test results and subsequent medical decision-making by multiple physicians.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.85%
Tags
none
Rhea-AI Summary
Lucid Diagnostics Inc. has released positive interim data from the multicenter CLUE study, demonstrating the real-world clinical utility of EsoGuard Esophageal DNA testing. The study shows excellent concordance between test results and subsequent medical decision-making by multiple physicians.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.18%
Tags
none
-
Rhea-AI Summary
Lucid Diagnostics announces positive data from a study demonstrating clinical utility of EsoGuard® Esophageal DNA testing in fire fighters
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.88%
Tags
none
-
Rhea-AI Summary
Lucid Diagnostics announces positive data from a study demonstrating clinical utility of EsoGuard® Esophageal DNA testing in fire fighters
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.2%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.84%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.75%
Tags
conferences
-
PAVmed Inc

Nasdaq:PAVMZ

PAVMZ Rankings

PAVMZ Stock Data

8.08M
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
US
New York

About PAVMZ

pavmed is a groundbreaking medical device company bringing innovative medical technologies from concept to commercialization with unprecedented speed and efficiency. led by three accomplished medical device entrepreneurs and organized to conceive, develop and commercialize a diversified pipeline of innovative products we believe address unmet clinical needs, our goal is to enhance and accelerate value creation by employing a business model focused on capital and time efficiency.